INDIA ANTICOAGULANTS MARKET FORECAST 2021-2025

  • You are here:
  • Home
  • Reports
  • INDIA ANTICOAGULANTS MARKET FORECAST 2021-2025

INDIA ANTICOAGULANTS MARKET FORECAST 2021-2025

The India anticoagulants market is projected to register a CAGR of 9.72%, over the forecast years. The country’s market growth is mainly driven by factors such as the increased prevalence of chronic obstructive pulmonary disease (COPD), the high incidence of cardiovascular diseases (CVDs), and the introduction of newer oral anticoagulants (NOACs). The base year considered for the market study is 2020, and the forecast years are from 2021 to 2025.

INDIA ANTICOAGULANTS MARKET FORECAST 2021-2025

India Anticoagulants Market by Application (Atrial Fibrillation & Heart Attack, Pulmonary Embolism (Pe), Deep Vein Thrombosis (Dvt), Stroke, Other Applications) by Route of Administration (Oral Anticoagulants, Injectable Anticoagulants) by Drug Class (Noacs, Heparins & Low-molecular-weight Heparins (Lmwhs), Vitamin K Antagonists, Other Drug Class)

Request free sample

The India anticoagulants market is projected to register a CAGR of 9.72%, over the forecast years. The country’s market growth is mainly driven by factors such as the increased prevalence of chronic obstructive pulmonary disease (COPD), the high incidence of cardiovascular diseases (CVDs), and the introduction of newer oral anticoagulants (NOACs). The base year considered for the market study is 2020, and the forecast years are from 2021 to 2025.
india-anticoagulants-market

To learn more about this report, request a free sample copy

According to the University of Washington’s Global Burden of Diseases Report, chronic obstructive pulmonary disorder (COPD) was considered India’s second-largest cause of death in 2017, claiming the lives of nearly 1 million Indians. Inhaled heparin is utilized as effective add-on therapy in patients with asthma and COPD, in order to prevent lung coagulation and inflammation. As a result, the increased incidence of such respiratory conditions is anticipated to increase anticoagulants’ demand in India.

Conversely, according to the report by Prabha Desikan et al., (2019), published in Circulation: Cardiovascular Quality and Outcomes, cardiovascular diseases (CVDs) are the leading cause of death in India. The epidemiological transition occurs primarily due to the increased prevalence of CVDs, in addition to their risk factors. For instance, nearly 1 in 4 deaths in India are caused by CVDs, with strokes and ischemic heart diseases accounting for more than 80% of the total figure. Hence, these factors are set to drive market growth, over the forecast period.

Dr. Reddy’s Laboratories, headquartered in Hyderabad, India, is among the leading pharmaceutical firms engaged in businesses, like active pharmaceutical ingredients (APIs), pharmaceutical services, and biologics. The enterprise provides over 350 high-quality generic drugs, and is one of the most extensive manufacturers of APIs, worldwide. Its operations extend across 38 nations, including Europe, Asia, and North America.

 

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    • MARKET SIZE & ESTIMATES
    • COUNTRY SNAPSHOT
    • COUNTRY ANALYSIS
    • KEY GROWTH ENABLERS
    • KEY CHALLENGES
  3. KEY ANALYTICS
    •    PORTER’S FIVE FORCES ANALYSIS
      • THREAT OF NEW ENTRY
      • THREAT OF SUBSTITUTION
      • BUYER’S POWER
      • SUPPLIER’S POWER
      • COMPETITIVE RIVALRY
    • IMPACT OF COVID-19 ON ANTICOAGULANTS MARKET
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
    • KEY INVESTMENT INSIGHTS
  4. MARKET BY APPLICATION
    • ATRIAL FIBRILLATION & HEART ATTACK
    • PULMONARY EMBOLISM (PE)
    • DEEP VEIN THROMBOSIS (DVT)
    • STROKE
    • OTHER APPLICATIONS
  5. MARKET BY ROUTE OF ADMINISTRATION
    • ORAL ANTICOAGULANTS
    • INJECTABLE ANTICOAGULANTS
  6. MARKET BY DRUG CLASS
    • NOACS
    • HEPARINS & LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS)
    • VITAMIN K ANTAGONISTS
    • OTHER DRUG CLASS
  7. COMPETITIVE LANDSCAPE
    •    KEY STRATEGIC DEVELOPMENTS
      • MERGER & ACQUISITIONS
      • PRODUCT LAUNCH & DEVELOPMENTS
      • PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
      • BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
    •    COMPANY PROFILE
      • ABBOTT LABORATORIES
      • DAIICHI SANKYO
      • REDDY’S LABORATORIES
      • JOHNSON & JOHNSON
      • PFIZER INC

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – ANTICOAGULANTS

TABLE 2: INDIA ANTICOAGULANTS MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 3: INDIA ANTICOAGULANTS MARKET, BY APPLICATION, FORECAST YEARS, 2021-2025 (IN $ MILLION)

TABLE 4: INDIA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 5: INDIA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, FORECAST YEARS, 2021-2025 (IN $ MILLION)

TABLE 6: INDIA ANTICOAGULANTS MARKET, BY DRUG CLASS, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 7: INDIA ANTICOAGULANTS MARKET, BY DRUG CLASS, FORECAST YEARS, 2021-2025 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

FIGURE 2: OPPORTUNITY MATRIX

FIGURE 3: VENDOR LANDSCAPE

FIGURE 4: KEY INVESTMENT INSIGHTS

FIGURE 5: INDIA ANTICOAGULANTS MARKET, BY APPLICATION, IN 2020

FIGURE 6: INDIA ANTICOAGULANTS MARKET, BY ATRIAL FIBRILLATION & HEART ATTACK, 2021-2025 (IN $ MILLION)

FIGURE 7: INDIA ANTICOAGULANTS MARKET, BY PULMONARY EMBOLISM (PE), 2021-2025 (IN $ MILLION)

FIGURE 8: INDIA ANTICOAGULANTS MARKET, BY DEEP VEIN THROMBOSIS (DVT), 2021-2025 (IN $ MILLION)

FIGURE 9: INDIA ANTICOAGULANTS MARKET, BY STROKE, 2021-2025 (IN $ MILLION)

FIGURE 10: INDIA ANTICOAGULANTS MARKET, BY OTHER APPLICATIONS, 2021-2025 (IN $ MILLION)

FIGURE 11: INDIA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, IN 2020

FIGURE 12: INDIA ANTICOAGULANTS MARKET, BY ORAL ANTICOAGULANTS, 2021-2025 (IN $ MILLION)

FIGURE 13: INDIA ANTICOAGULANTS MARKET, BY INJECTABLE ANTICOAGULANTS, 2021-2025 (IN $ MILLION)

FIGURE 14: INDIA ANTICOAGULANTS MARKET, BY DRUG CLASS, IN 2020

FIGURE 15: INDIA ANTICOAGULANTS MARKET, BY NOACS, 2021-2025 (IN $ MILLION)

FIGURE 16: INDIA ANTICOAGULANTS MARKET, BY HEPARINS & LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS), 2021-2025 (IN $ MILLION)

FIGURE 17: INDIA ANTICOAGULANTS MARKET, BY VITAMIN K ANTAGONISTS, 2021-2025 (IN $ MILLION)

FIGURE 18: INDIA ANTICOAGULANTS MARKET, BY OTHER DRUG CLASS, 2021-2025 (IN $ MILLION)

  1. MARKET BY APPLICATION
    • ATRIAL FIBRILLATION & HEART ATTACK
    • PULMONARY EMBOLISM (PE)
    • DEEP VEIN THROMBOSIS (DVT)
    • STROKE
    • OTHER APPLICATIONS
  2. MARKET BY ROUTE OF ADMINISTRATION
    • ORAL ANTICOAGULANTS
    • INJECTABLE ANTICOAGULANTS
  3. MARKET BY DRUG CLASS
    • NOACS
    • HEPARINS & LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS)
    • VITAMIN K ANTAGONISTS
    • OTHER DRUG CLASS

To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now